Omeros
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Omeros and other ETFs, options, and stocks.About OMER
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market.
OMER Key Statistics
Stock Snapshot
With a market cap of 1.18B, Omeros(OMER) trades at $16.52. The stock has a price-to-earnings ratio of -8.21.
During the trading session on 2025-12-29, Omeros(OMER) shares reached a daily high of $16.64 and a low of $14.44. At a current price of $16.52, the stock is +14.4% higher than the low and still -0.7% under the high.
Trading volume for Omeros(OMER) stock has reached 5.56M, versus its average volume of 5.16M.
Over the past 52 weeks, Omeros(OMER) stock has traded between a high of $17.65 and a low of $2.95.
Over the past 52 weeks, Omeros(OMER) stock has traded between a high of $17.65 and a low of $2.95.
OMER News
Investors eyeing a purchase of Omeros Corp (Symbol: OMER) stock, but cautious about paying the going market price of $15.34/share, might benefit from considerin...
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Friday. Shares of Biohaven Ltd (NYSE:BHVN) fell sharply in pre-market t...
The company is on the brink of commercializing a unique medication. For the most part, the stock market tends to be sedate in the late holiday season. That sur...
More OMER News
U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday. the Dow traded up 0.48% to 48,673.55 whil...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ:OMER) Yartemlea (narsoplimab-wuug) for hematopoietic stem cell tran...
D. Boral Capital notes that Omeros (OMER) announced FDA approval of YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic micr...
Omeros Corporation (OMER) announced on Wednesday that the U.S. FDA approved its lead asset, narsoplimab-wuug, as a treatment for hematopoietic stem cell transpl...
